Metagenomic Virome Sequencing in Living Donor and Recipient Kidney Transplant Pairs Revealed JC Polyomavirus Transmission

Peter W. Schreiber,1,a Verena Kufner,2,a Kerstin Hübel,3 Stefan Schmutz,2, Osvaldo Zagordi,2, Amandeep Kaur,1, Cornelia Bayard,1, Michael Greiner,1 Andrea Zbinden,2 Riccarda Capaul,2 Jürg Böni,2 Hans H. Hirsch,7 Thomas F. Mueller,3 Nicolas J. Mueller,1,b Alexandra Trkola,2,b and Michael Huber2,b

1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich; 2 Institute of Medical Virology, and 3 Department of Nephrology, University Hospital Zurich, University of Zurich; 4 Department of Biomedicine, University of Basel, Switzerland

**Background.** Before kidney transplantation, donors and recipients are routinely screened for viral pathogens using specific tests. Little is known about unrecognized viruses of the urinary tract that potentially result in transmission. Using an open metagenomic approach, we aimed to comprehensively assess virus transmission in living-donor kidney transplantation.

**Methods.** Living kidney donors and their corresponding recipients were enrolled at the time of transplantation. Follow-up study visits for recipients were scheduled 4–6 weeks and 1 year thereafter. At each visit, plasma and urine samples were collected and transplant recipients were evaluated for signs of infection or other transplant-related complications. For metagenomic analysis, samples were enriched for viruses, amplified by anchored random polymerase chain reaction (PCR), and sequenced using high-throughput metagenomic sequencing. Viruses detected by sequencing were confirmed using real-time PCR.

**Results.** We analyzed a total of 30 living donor and recipient pairs, with a follow-up of at least 1 year. In addition to viruses commonly detected during routine post-transplant virus monitoring, metagenomic sequencing detected JC polyomavirus (JCPyV) in the urine of 7 donors and their corresponding recipients. Phylogenetic analysis confirmed infection with the donor strain in 6 cases, suggesting transmission from the transplant donor to the recipient, despite recipient seropositivity for JCPyV at the time of transplantation.

**Conclusions.** Metagenomic sequencing identified frequent transmission of JCPyV from kidney transplant donors to recipients. Considering the high incidence rate, future studies within larger cohorts are needed to define the relevance of JCPyV infection and the donor’s virome for transplant outcomes.

**Keywords.** kidney transplantation; metagenomic sequencing; virus infection; JC polyomavirus.

Donor-derived infections after solid organ transplantation range from rare to very common, and from life-threatening to subclinical [1]. Recommendations for pre-transplant screening of organ recipients and donors for latent or active viral infections have been issued and are included in routine pre-transplant care [2]. This screening aims to identify donors with infections that would disqualify them for donation or require prophylactic strategies in the recipient. The most common example for the latter is cytomegalovirus (CMV), where transmission is considered an acceptable risk, if prevention strategies are in place. BK polyomavirus (BKPvV) has been associated with post-transplant complications causing polyomavirus-associated nephropathy (PyVAN), which increases the risk of allograft failure in 1–15% of transplant recipients [3, 4].

Besides these established viral infections, the role of additional pathogens in the donor’s virome is understudied. This is surprising, as there are ample examples that the transmission of pathogenic viruses, albeit commonly rare, can occur. Prominent examples in renal transplantation are West Nile virus [5], lymphocytic choriomeningitis virus [6], human gammaherpesvirus 8 [7], and rabies lyssavirus [8]. Analyses of the virome thus far have focused solely on the kidney transplant recipients [9, 10]. Urinary tract infections of kidney transplant recipients with BKPvV and JC polyomavirus (JCPyV) were associated with complications occurring after transplantation [9, 11–13]. Whether these viruses were reactivated from latency under immunosuppressive therapy or were transferred from donor to recipient has not been resolved. In 1 study, identical BKPvV genome sequences in donors and recipients indicated transmission via the graft [14].

JCPyV Transmission in Kidney Transplants • CID 2019:69 (15 September) • 987
The growing uncertainty over which viruses need to be monitored and the relevance of the donor as a significant, but rarely studied, source of transmission prompted us to conduct a prospective, systematic characterization of the virome in a cohort of both kidney donors and their corresponding recipients. Participants were monitored at the time of transplantation and up to 1 year post-transplant using an open, metagenomic approach.

**MATERIAL AND METHODS**

**Ethical Statement**

Samples were obtained from living kidney transplant donors and recipients within the Viral Metagenome Study of the Clinical Research Priority Program ‘Viral Infectious Diseases’ of the University of Zurich. The Ethics Committee of the Canton of Zurich approved the study, and written informed consent was obtained from all participants (protocol number KEK-ZH-Nr. 2013-0087).

**Transplant Cohort**

Recipients of kidney grafts and their corresponding living donors were enrolled at the time of transplantation. For kidney graft recipients, consecutive, post-transplant study visits were planned at 4–6 weeks and 1 year after transplantation. For living kidney donors, a single visit at the time of organ donation was scheduled. At each visit, plasma and urine samples were collected and recipients were evaluated for signs of infection or present BK viremia, graft function, and transplant-related complications. The cohort was divided in 2 subsets, based on chronological order.

**Immunosuppressive Therapy and Antimicrobial Prophylaxis**

Induction immunosuppression therapy was administered to all 30 recipients, consisting of methylprednisolone (500 mg on day of surgery) and either basiliximab (20 mg on day of surgery and on day 4) or anti-thymocyte immunoglobulin (ATG) (1.5 mg/kg body weight on day of surgery and on post-transplant days 1–4). The most common regimen for maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil, and prednisone.

Kidney transplant recipients received *Pneumocystis jirovecii* prophylaxis with trimethoprim/sulfamethoxazole at 400/80 mg daily for 6 months post-transplant. Topical antifungal prophylaxis with amphotericine B pastilles at 10 mg 4 times a day was supervised and the relevance of the donor as a significant, but rarely studied, source of transmission prompted us to conduct a prospective, systematic characterization of the virome in a cohort of both kidney donors and their corresponding recipients. Participants were monitored at the time of transplantation and up to 1 year post-transplant using an open, metagenomic approach.

Recipients with intermediate or high-risk CMV constellation were pooled for library construction with NexteraXT (Illumina) RNA and DNA were amplified using random reverse transcription and anchored PCR in 2 separate workflows. Both workflows were pooled for library construction with NexteraXT (Illumina) prior to sequencing for 150 bp on an Illumina MiSeq system.

**RESULTS**

**Study Characteristics**

To define the virome of kidney transplant recipients and their living donors, a total of 30 kidney transplant pairs were included in our study. In 10 out of 30 patients (33.3%), kidney transplantation was preemptive; 20 patients (66.6%) were on renal replacement therapy prior to transplant, with 16 receiving hemodialysis and 4 peritoneal dialysis (Table 1). For 28 transplant recipients, follow-up data for at least 1 year post-transplant was available. No major complications and only few symptomatic episodes occurred during this period. There were 5 recipients who experienced symptoms suggestive of infections, such as fever, gastroenteritis, or inflammatory syndrome (Supplementary Figure 1) at the time points of study visits.

**Conventional Viral Diagnostics in Kidney Transplant Recipients**

In the context of routine post-transplant care, viral quantitative PCR (qPCR) monitoring detected BKPyV and CMV in the blood samples of 20 recipients. Standard laboratory analyses detected several cases of respiratory viruses, such as influenza A and B virus, rhinovirus, or coronavirus, in throat swabs (Figure 1).

**Metagenomic Sequencing of Blood and Urine Samples of Donors and Recipients**

Our goal was to obtain a comprehensive overview of the viral metagenome of kidney donors and corresponding recipients.
Table 1. Demographics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Recipients</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total, N</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>11 (36.6%)</td>
<td>12 (40%)</td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>14 (93.3%)</td>
<td>29 (96.7%)</td>
</tr>
<tr>
<td>Asian</td>
<td>2 (6.7%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>Age, in years, median (IQR)</td>
<td>44.5 (32–55)</td>
<td>56 (52–64)</td>
</tr>
<tr>
<td>Underlying disease, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>9 (30.0%)</td>
<td></td>
</tr>
<tr>
<td>ADPKD</td>
<td>4 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>Hereditary cause other than ADPKD</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Congenital disease</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Hypertensive nephropathy</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Multifactorial</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Other causes</td>
<td>5 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>Renal replacement therapy, pre-transplant, n (%)</td>
<td>10 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>16 (53.3%)</td>
<td></td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
<td>4 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>Induction immunosuppression, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basilicalemb/methylprednisolone</td>
<td>24 (80.0%)</td>
<td></td>
</tr>
<tr>
<td>ATG/methylprednisolone</td>
<td>6 (20.0%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ATG, anti-thymocyte immunoglobulin; IQR, interquartile range.

For 14 living kidney donors and their recipients (subset 1), blood and urine samples from the time of transplantation (donors and recipients), as well as 4–6 and 52 weeks after transplantation (recipients), were analyzed by metagenomic sequencing. In 6 donors, reads for JCPyV were detected in urine samples at the time of transplantation. No other viral reads were identified in the donors, except TTV in blood (n = 4). In the urine of the kidney transplant recipients, JCPyV was found in 5 recipients, BKPyV in 4, human papilloma virus (HPV) in 4, and TTV in 3 (Figure 2; Supplementary Table 2). Interestingly, in 5 of 6 cases of JCPyV-positive donors, JCPyV was also detected in the urine samples of the respective recipients at 4–6 weeks or 1 year after transplantation. In the blood of kidney recipients, TTV was found in 11 recipients and BKPyV in 1 recipient.

Sequence-specific Quantitative Polymerase Chain Reaction in Subset 1 Patients

To confirm the findings obtained by metagenomic sequencing, blood and urine samples of all time points of subset 1 donors and recipients were tested by virus-specific qPCRs for BKPyV, JCPyV, and TTV. Individual patient-virus specific PCR systems were designed for HPV for suspected cases. PCR analyses confirmed all cases of BKPyV, JCPyV, HPV, and TTV infection reported by metagenomic sequencing, and revealed further positive cases amongst recipients that were not detected by metagenomic sequencing. The additional infections were detected in urine (1 BKPyV, 2 JCPyV; Supplementary Table 3A) and blood (8 BKPyV, 2 JCPyV; Supplementary Table 3B).

Sequence-specific Quantitative Polymerase Chain Reaction in Subset 2 Patients

We next used subset 2 to investigate whether the viruses that were predominantly found by metagenomics analyses in subset 1—namely, BKPyV, JCPyV, and TTV—were generally prevalent. Sequence-specific qPCRs for these 3 viruses were performed in blood and urine samples of the remaining 16 living-donor kidney transplant pairs. We identified 2 additional cases of JCPyV-positive donor-recipient pairs (tvy653, ume111) and 1 case of JCPyV detection that was only in the donor (sjp926). BKPyV was detected in the urine of 4 recipients (Supplementary Table 3A).

Phylogenetic Analysis of JC Polyomavirus Isolates Revealed Clusters of Donor-Recipient Pairs

Combining subsets 1 and 2, we detected JCPyV in 9 of the 30 kidney donors at the time of transplantation. The corresponding recipients were JCPyV-negative at this time point in 8 out of the 9 cases. There were 7 recipients who tested positive for JCPyV in urine, either at 4–6 weeks and/or 1 year post-transplant (Figure 2; Supplementary Table 2), while 2 recipients stayed negative for JCPyV after transplantation, despite positive donors.

To define whether JCPyV in recipients is due to transmission from the donor or to latent reactivation, we constructed consensus sequences of the JCPyV isolates in donors and recipients. For this purpose, candidate samples from subset 2 were sequenced as well (Supplementary Table 2). Full genome coverage was achieved in all cases, except for jns976, where only between 25% and 80% of the genome was covered (Supplementary Figure 4). Phylogenetic analysis revealed a tight clustering of JCPyV sequences in donor-recipient pairs in 6 out of 7 cases (Figure 3), implying that, in these cases, JCPyV infection was contracted from the donor. In the remaining pair (jns976), despite lower coverage, the phylogenetic analysis revealed that more distinct strains infected donor and recipient. Of note, recipient jns976 was already positive for JCPyV at the time of transplantation (Figure 2).

JC Polyomavirus Serology Detected High Prevalence of JC Polyomavirus–specific Antibodies

In order to confirm or exclude pre-transplant JCPyV infections, we performed IgG-specific serology for all participants at the time of transplantation. There were 21 donors and 27 recipients sero-positive for JCPyV, corresponding to a seroprevalence of 80% among all 60 individuals. In the 6 recipients with JCPyV transmission from the donor, the IgG serology revealed the presence of virus-specific antibodies from before the transplantation (Supplementary Table 4).

An interesting case was recipient jns976, who was seronegative at the time of transplantation, although being positive...
for JCPyV. Therefore, we additionally performed IgG and IgM serology for 2 time points before (-4 months and -1 day) and 2 time points after transplantation (4–6 weeks and 1 year). JCPyV-specific IgM was negative at all time points. In contrast, JCPyV-specific IgG was low positive at 4 months and 1 day prior to transplantation, as well as 1 year after, but undetectable 4–6 weeks after transplantation (Supplementary Table 5).

Torque Teno Virus Levels Increased After Initiation of Immunosuppressive Therapy
As shown for other cases of transplantation-related immunosuppression, TTV loads increased in all kidney transplant recipients after transplantation. Viral loads reached their highest levels at 4–6 weeks post-transplantation (Supplementary Figure 2). We did not find any significant difference in the viral load of TTV in recipients with or without CMV or BKPyV replication, respectively.

Low Prevalence of Human Pegivirus in Kidney Transplant Cohort
HPgV was recently reported as a predominant and persistent component of the blood virome in immunosuppressed patients after transplantation [18]. As our metagenomic analysis of subset 1 recipients did not pick up HPgV in any of the tested samples, we searched for HPgV by specific PCR in both subset 1 and subset 2 recipients. We detected only a single case of HPgV, in a subset 2 recipient who was not studied by metagenomics before.

Effect of Induction Immunosuppression on JC Polyomavirus Replication
All recipients received induction immunosuppression, with most of them treated with basiliximab/methylprednisolone (80%) and the minority with ATG/methylprednisolone (20%; Table 1). All cases of JCPyV replication were detected in patients receiving induction immunosuppression with basiliximab/methylprednisolone (7 of 24 recipients), whereas none of the recipients with administration of ATG/methylprednisolone tested positive for JCPyV replication (Fisher’s exact test, \( P = 0.29 \)).

Parameters of Renal Function and JC Polyomavirus Infection
To investigate whether JCPyV infection had an influence on renal function, we compared estimated glomerular filtration...
rates and proteinuria in JCPyV-positive and -negative kidney transplant recipients. We did not detect any significant differences in estimated glomerular filtration rates (Supplementary Figure 3A) and protein/creatinine ratios (Supplementary Figure 3B) between transplant recipients with or without JCPyV infection.

**DISCUSSION**

Here, we studied the viral metagenomes of living kidney transplant donors and their corresponding recipients. The analysis of a first subset of 14 patient pairs by our open metagenomic approach identified JCPyV in the urine samples of 6 donors and BKPyV, JCPyV, HPV, and TTV replication in the urine samples of 9 recipients, which were confirmed by specific PCR. PCR screening of a second subset for the same viruses identified JCPyV in the urine samples of 3 donors, with 2 additional cases of JCPyV replication in donors and corresponding recipients.

The presence of JCPyV in the urine of kidney donors at the time of transplant and in the corresponding kidney recipients 4–6 or 52 weeks after transplantation strongly suggested transmission of JCPyV via the graft. Phylogenetic analysis confirmed a transmission in 6 of 9 positive donors to the recipient, despite the seropositive immune status of the recipient. Only 1 additional recipient developed JC viruria, supporting the importance of donor-derived JCPyV infection in living donor kidney transplantation.

Notably, JCPyV-specific serology revealed the presence of virus-specific antibodies at the time of transplantation in these 6 cases. This is in line with previous reports [23] and the seroprevalence of 80% among the 60 individuals in this cohort. Nevertheless, prior immune responses did not prevent nor rule out transmission (super infection) during transplantation, especially in kidney transplantation as the organ of JCPyV persistence.

**Figure 2.** Metagenomic sequencing of subset 1 suggests JC polyomavirus transmission. Negative and positive sequencing results (dashes and closed circles, respectively) determined in urine (upper panels) and blood samples (lower panels) of donors (left panels) and respective recipients (right panels) of subset 1 for sampling time points 0, 4–6, and 52 weeks after transplantation.
In 1 patient (jns976), the JCPyV sequences of the donor and recipient did not cluster. Here, we initially suspected a recent infection of the recipient, as the individual was IgG negative at the time of transplant but, at the same time, JCPyV reads could be detected, which has been reported before in cases of primary JCPyV infection in kidney transplant patients [22, 24, 25]. Surprisingly, the patient was already IgG positive before transplantation, as well as 1 year thereafter, while IgG levels were undetectable around the time of transplantation. IgM levels were undetectable at all time points. The reasons for these observations remain unclear. This transplant recipient did not receive immunosuppressive therapy—especially, no B-cell–depleting therapy—prior to transplantation, which could have lowered the specific IgG levels assessed at the time of transplantation [26].

The impact of JCPyV replication after renal transplantation is only emerging. Several studies reported the detection of the virus in the urine of kidney transplant recipients [9, 27]. In the context of immunosuppressed individuals, JCPyV has been associated with 2 clinical entities: that is, progressive multifocal leukoencephalopathy and PyVAN [28]. However, in contrast to BKPyV, JCPyV has been rarely observed as a causative pathogen for PyVAN [22, 29]. Different results have been stated in the literature regarding JCPyV viruria and its impact on transplant outcomes. On the one hand, JCPyV urinary shedding was associated with reduced creatinine clearance in kidney and liver transplant patients, and might therefore play a role in renal dysfunction [30]. On the other hand, the finding of JCPyV viruria was shown to correlate with a favorable clinical course, especially if detected early [25]. Interestingly, Cheng et al reported better graft survival and lower rejection rates in kidney recipients with JCPyV viruria [31]. Also, in our study, clinically and on renal function, no impact was seen. In studies with larger numbers, longer periods of observation and, presumably, in deceased donor kidney transplantation, the relevance might be higher.

The literature suggests a frequent donor origin for BKPyV viremia after kidney transplantation [32, 33]. Considering the
mission, its relevance for the transplant outcomes, graft losses, and life expectancies of recipients need to be investigated in larger cohorts.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank all the participating individuals and the staff of the Department of Nephrology at the University Hospital Zurich. Plasmid pAF121950 was obtained from Laurent Kaiser and Samuel Corday (originally from the National Institutes of Health Acquired Immunodeficiency Syndrome Reagent Program, Division of Acquired Immunodeficiency Syndrome, NIAID, National Institutes of Health, Dr. Jinhua Xiang and Dr. Jack Stapleton).

Financial support. This work was supported by the Clinical Research Priority Program 'Viral Infectious Diseases' of the University of Zurich.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

39. Kaiser L. Virome and transplantation. Available at: https://www.escmid.org/escmid_publications/escmid_eibrary/?q=laurent+kaiser&f=2&173&l=0&x=0&y=0&tx_soli%5Bsort%5D=relevance%2Basc&tx_soli%5Bfilter%5D%5B0%5D=main_filter_escmid%253Atrue&tx_soli%5Bfilter%5D%5B1%5D=pub_date%253A201801010000-201812312359. Accessed 20 December 2018.